Zepatier Is FDA-Approved to Treat Hepatitis C
Share
Follow Us
The Editors at Hepatitis Central
January 29, 2016
Less costly than previously approved treatments, learn more about Merck’s newly FDA-approved Zepatier for Hepatitis C patients.
FDA OKs Merck’s Zepatier (Grazoprevir/Elbasvir) to Treat Hep C
The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir), with or without ribavirin, to treat those with genotypes 1 and 4 hepatitis C virus (HCV).
Zepatier (ZEP’-ah-teer”) includes NS3/4A protease inhibitor grazoprevir and the NS5A replication complex inhibitor elbasvir.
Continue reading this entire article:
https://www.hepmag.com/article/fda-oks-mercks-zepatier-grazoprevirelbasvir-treat-hepatitis-c
2 Comments
Thank you, Merck for paying attention to us Hepatitis C sufferers. And thank you for giving a message to Gilead by making your tx 1/2 the price of existing companies. Your company has manufactured medicines for Hep C for 25 years. I have a feeling that you are motivated not simply for money. If so. we appreciate it.
I’m 81 and completed my Merck clinical trial 2 years ago and remain SVR. Easy trial–even with ribavirin. That was the arm of the trial I got. So glad it is finally available for geno 1 and 3 or 4. can’t remember which. Gilead refused me for their trials because I had cirrhosis.